Silver Book Fact

Cost-savings associated with Warfarin use in AFib patients

Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.

Mercaldi, CJ, M Ciaramentaro, B Hahn, G Chalissery, MW Reynolds, SD Sander, GP Samsa, and DB Matchar. Cost Efficiency of Anticoagulation with Warfarin to Prevent Stroke in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation. Stroke. 2011; 42(1): 112-8. http://stroke.ahajournals.org/cgi/content/short/42/1/112

Reference

Title
Cost Efficiency of Anticoagulation with Warfarin to Prevent Stroke in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation
Publication
Stroke
Publication Date
2011
Authors
Mercaldi, CJ, M Ciaramentaro, B Hahn, G Chalissery, MW Reynolds, SD Sander, GP Samsa, and DB Matchar
Volume & Issue
Volume 42, Issue 1
Pages
112-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.  
  • Atrial fibrillation ablation prevents recurrence of AFib
    Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…  
  • Stroke prevention through optimal anticoagulation
    If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.  
  • Effectiveness of pacemaker/defibrillators to control AFib
    Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.  
  • Decrease in AFib hospitalization rates
    The use of practice guidelines in atrial fibrillation patients saw a decrease in rate of hospitalization from 74%to 38%.